First Major Texas Metropolitan Area Police Department Joins COPsync Network
Mar 17, 2016 13:00 pm UTC| Business
DALLAS, March 17, 2016 -- COPsync, Inc. (NASDAQ:COYN), which operates the nation's only law enforcement in-car, real-time information sharing and data communication network and the COPsync911™ threat-alert service for...
Liberty Property Trust Updates Disposition Activity
Mar 17, 2016 12:50 pm UTC| Business
MALVERN, Pa., March 17, 2016 -- Consistent with Liberty’s publicly-stated intent to sell approximately $900 million to $1.2 billion of non-core suburban properties in 2016, we have entered into discussions with a...
Advecta(TM) II Launches at Target Stores Nationwide
Mar 17, 2016 12:47 pm UTC| Business
EAGLE, Idaho, March 17, 2016 -- Advecta II, a new affordable and easy-to-use flea solution for dogs and cats, is now available at Target and other stores nationwide. Advecta II comes in a 4-month supply and offers...
Beazley and Boston Mutual sign marketing agreement
Mar 17, 2016 12:47 pm UTC| Business
MINNEAPOLIS, March 17, 2016 -- Beazley U.S. Accident Health has entered into a new marketing agreement with Boston Mutual Life Insurance Company, a national provider of insurance solutions for individuals and at the...
Fifth Street Asset Management Inc. Announces Fourth Quarter and Full Year 2015 Results
Mar 17, 2016 12:37 pm UTC| Business
GREENWICH, CT, March 17, 2016 -- Fifth Street Asset Management Inc. (NASDAQ:FSAM) ("FSAM" or "we") announces its financial results for the fourth quarter and year ended December31, 2015. Fourth Quarter and Full Year...
EDAP HIFU and Lithotripsy Devices Showcased at 31st Annual European Association of Urology Congress
Mar 17, 2016 12:30 pm UTC| Business
LYON, France, March 17, 2016 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its HIFU and lithotripsy devices were highlighted at the European Association of Urology (EAU)...
Mar 17, 2016 12:30 pm UTC| Business
REDWOOD CITY, Calif., March 17, 2016 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first...